Results of SAVANNAH, a phase II study comprised of "one of the largest datasets evaluating an oral MET tyrosine kinase inhibitor in EGFR-mutated non-small cell lung cancer" was recently reported in Annals of Oncology. Considered to be the first study to use a novel biomarker-based patient selection strategy, results from SAVANNAH "demonstrate efficacy benefit with a chemotherapy-free, orally administered, combined EGFR and MET targeted treatment regimen."
To learn more about the SAVANNAH study, click here.
Source mentioned:
de Marinis F, Kim TM, Bonanno L, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study . Annals of Oncology 2025;36(8):P920-933. DOI: https://doi.org/10.1016/j.annonc.2025.04.003
MET-driven resistance after first-line osimertinib is one of the most common dead ends in EGFR-mutated lung cancer, so a combination showing a high response in that exact setting is clinically important. Re-biopsy and resistance testing only help when there is a next step to offer, and savolitinib plus osimertinib looks like one. The two onc docs show notes are a good reference for how resistance mechanisms translate into practical next-line choices in lung cancer care.
ReplyDelete